查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2010054

抗肥胖藥物市場：依產品類型、劑型、給藥途徑及最終用戶分類－2026-2032年全球市場預測

Anti-Obesity Drugs Market by Product Type, Dosage Form, Route Of Administration, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，抗肥胖藥物市場價值將達到 43.8 億美元，到 2026 年將成長到 46.7 億美元，到 2032 年將達到 70.7 億美元，複合年成長率為 7.07%。

主要市場統計數據
基準年 2025 43.8億美元
預計年份：2026年 46.7億美元
預測年份 2032 70.7億美元
複合年成長率 (%) 7.07%

從策略角度審視現代抗肥胖治療領域，重點關注臨床進展、相關人員的期望以及專案永續成功所面臨的營運挑戰。

抗肥胖藥物的治療格局已從小眾臨床爭論發展成為生物製藥公司、保險公司和醫療保健系統的主流策略重點。新型經營團隊和聯合治療正在重新定義人們對持續減重和代謝改善的臨床預期，重新激發了商業、臨床和監管相關人員相關者的關注。這種轉變要求在快速的治療創新與長期安全性、用藥依從性和成本效益等實際挑戰之間取得平衡。

科學突破、不斷發展的報銷模式和新的給藥方法如何重新定義肥胖治療領域的競爭和護理路徑。

抗肥胖藥物市場正經歷一場變革性的轉變，其驅動力來自臨床突破和保險公司的模式轉移。腸促胰素生物學和雙重促效劑平台的突破顯著提高了藥物療效標準，改變了處方模式，並提高了人們對單純減重之外的持續代謝獲益的期望。這一科學動能正在引發一系列連鎖反應，包括擴大適應症範圍、考慮仿單標示外用藥物以及加劇直接比較競爭，最終重塑藥物生命週期規劃和商業性上市策略。

分析 2025 年美國關稅調整對整個減肥藥生態系統的連鎖反應，包括採購、製造重組、支付方保險覆蓋範圍和取得策略。

2025年美國關稅調整對整個抗肥胖治療價值鏈產生了連鎖反應，加劇了依賴進口零件的脆弱性，並改變了成品的成本計算方式。生物製藥和複雜小分子化合物的原料採購通常涉及多個國家的跨境運輸。半成品關稅的增加提高了接收成本，促使企業重新評估其供應商名單。為此，採購團隊加快了供應商多元化進程，並探索遠期合約以對沖投入品價格波動所帶來的風險。

將產品模式、劑型、給藥途徑和最終用戶環境與獨特的臨床和商業性機會聯繫起來的詳細細分分析。

基於細分市場的分析揭示了不同治療領域、劑型、給藥途徑和終端用戶的獨特機會和限制因素，這些因素將影響產品組合和商業策略。從產品類型來看，GLP-1促效劑和雙重促效劑因其高效性而備受臨床醫生青睞。同時，納曲酮/安非他酮、奧利司他、芬特明/托吡酯和SGLT2抑制劑等成熟藥物，在針對特定患者群體和合併症的處方中仍然發揮著至關重要的作用。由於作用機制和安全性特徵的差異，治療順序、合併用藥策略和禁忌症管理仍將是臨床訊息的核心主題。

美洲、歐洲、中東和非洲以及亞太地區在臨床應用率、支付方要求和監管複雜性方面的區域差異，正在推動各地採取不同的准入策略。

區域趨勢在臨床、監管和商業方面呈現出顯著特徵，因此需要製定本地化的市場進入和業務拓展策略。在美洲，強大的支付方影響力、大規模的臨床試驗部署以及患者對有效治療方法的高需求，共同創造了一個競爭激烈的環境，長期治療效果和成本效益證據至關重要。能夠適應基於價值的合約和完善患者支援體系的製造商，將在專科診所和廣泛的門診網路中都獲得支援。

透過證據生成、供應彈性以及綜合患者解決方案，制定競爭和企業策略，從而決定抗減肥藥領域的長期領導地位。

抗減肥藥市場的競爭格局由老牌製藥公司和創新生物技術公司共同組成。市場領導正利用其深厚的臨床開發能力拓展適應症並累積對比證據，而新參與企業則專注於差異化的作用機制、創新醫療設備或綜合性的病患支援提案。隨著各公司努力加速產品線成熟並擴大商業性影響力，策略聯盟、共同開發契約和收購等手段正變得越來越普遍。

為製藥公司和相關人員提供極具影響力和可操作性的建議，以確保藥物可及性、加強價值鏈，並在臨床實踐中最大限度地發揮治療價值。

行業領導者應優先考慮一系列切實可行的步驟，將臨床潛力與永續的商業性成果聯繫起來。首先，投資於分階段的證據生成計劃，該計劃將關鍵臨床試驗數據與旨在證明持續代謝效應和改善生活品質的可操作性真實世界研究相結合。儘早與保險公司和衛生技術評估機構合作，統一終點指標和證據包，將有助於減少後續准入的阻力。

一項嚴謹的多面向研究框架，結合了相關人員訪談、監管審查、臨床證據整合和情境分析，得出了策略性結論。

本執行摘要的研究結合了多種方法，以確保提供平衡且切實可行的見解。研究人員對內分泌科和肥胖症科的臨床醫生、醫院藥劑師、支付方政策制定者以及供應鏈高管進行了初步的定性訪談，以識別短期運營風險和推動技術應用的因素。此外，研究人員還系統地審查了監管和臨床指南文件以及公開的臨床試驗註冊信息，以檢驗影響治療定位、安全性訊號和保險覆蓋範圍等討論的關鍵終點指標。

結論強調，將臨床創新轉化為永續的患者療效需要證據協調、供應彈性以及在地化的准入策略。

現代抗肥胖藥物領域呈現前所未有的治療潛力，但同時也面臨複雜的取得途徑。科學創新提高了療效標準，並改變了人們對慢性病管理的預期，但供應鏈和監管的複雜性，以及對藥物可及性和可負擔性的考量，都在減緩這些治療方法轉化為人群層面療效的速度。因此，決策者必須整合臨床、營運和商業性計劃，才能實現長期價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：抗肥胖藥物市場：依產品類型分類

  • GLP-1促效劑
  • 納曲酮安非他酮
  • 奧利司他
  • 托吡拉芬特明
  • SGLT2抑制劑

第9章：以劑型分類的抗肥胖藥物市場

  • 膠囊
  • 注射藥物
    • 預填充筆
    • 管瓶
  • 藥片

第10章：抗肥胖藥物市場：依給藥途徑分類

  • 注射藥物
    • 自動噴油器
    • 預填充筆
    • 管瓶
  • 鼻內
  • 口服

第11章：抗肥胖藥物市場：依最終用戶分類

  • 診所
  • 居家醫療
  • 醫院

第12章：抗肥胖藥物市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：抗肥胖藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：抗肥胖藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國抗肥胖藥物市場

第16章：中國抗肥胖藥物市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alvogen Iceland EHF
  • Amgen Inc
  • Arena Pharmaceuticals Inc
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Currax Pharmaceuticals LLC
  • Eli Lilly and Company
  • F Hoffmann La Roche Ltd
  • GlaxoSmithKline plc
  • Innovent Biologics Inc
  • LG Chem Ltd
  • Merck and Co Inc
  • Novo Nordisk AS
  • Pfizer Inc
  • Rhythm Pharmaceuticals Inc
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
  • VIVUS LLC
  • Zydus Lifesciences Ltd
Product Code: MRR-434CCDA05185

The Anti-Obesity Drugs Market was valued at USD 4.38 billion in 2025 and is projected to grow to USD 4.67 billion in 2026, with a CAGR of 7.07%, reaching USD 7.07 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.38 billion
Estimated Year [2026] USD 4.67 billion
Forecast Year [2032] USD 7.07 billion
CAGR (%) 7.07%

A strategic orientation to the modern anti-obesity therapy environment emphasizing clinical advances, stakeholder expectations, and operational imperatives for sustained program success

The therapeutic landscape for anti-obesity drugs has evolved from a niche clinical conversation into a mainstream strategic priority for biopharma, payers, and health systems. Novel incretin-based agents and combination therapies have reshaped clinical expectations for durable weight loss and metabolic benefit, prompting fresh interest across commercial, clinical, and regulatory stakeholders. This shift requires executives to reconcile rapid therapeutic innovation with real-world considerations such as long-term safety, adherence modalities, and cost-effectiveness.

Clinicians are increasingly viewing obesity as a chronic disease that demands sustained pharmacologic intervention alongside lifestyle modification. Payers are responding with conditional coverage frameworks that emphasize outcomes and value-based contracting. Simultaneously, manufacturing and distribution ecosystems are adapting to the unique requirements of injectable formulations and complex biologics. Taken together, these cross-cutting forces create both opportunity and complexity for organizations seeking to launch or scale anti-obesity therapeutics.

This introduction frames the rest of the executive summary by highlighting the intersection of innovation, access, and systems-level readiness. The following sections outline the transformative shifts in the therapeutic landscape, tariff-related supply chain implications, segmentation-driven commercial insights, regional dynamics, competitive positioning, actionable recommendations, methodological underpinnings, and concluding priorities for decision-makers. Each element is intended to inform strategic planning, identify operational risks, and prioritize high-impact interventions for near- and mid-term horizons.

How scientific breakthroughs, evolving reimbursement models, and new delivery modalities are jointly redefining competitive dynamics and care pathways in obesity therapeutics

The anti-obesity drug landscape is undergoing transformative shifts driven by simultaneous clinical breakthroughs and evolving payer paradigms. Breakthroughs in incretin biology and dual-agonist platforms have materially raised efficacy benchmarks, altering prescribing patterns and elevating expectations for sustained metabolic benefit beyond weight reduction alone. This scientific momentum has catalyzed a cascade of label expansions, off-label prescribing considerations, and intensified head-to-head competition, which in turn is reshaping life-cycle planning and commercial launch strategies.

Concurrently, reimbursement frameworks are adapting. Payer strategies now increasingly emphasize longitudinal outcomes, tiered access, and novel contracting models that tie reimbursement to performance metrics. Health systems are reorienting care pathways to integrate pharmacotherapy into multidisciplinary obesity management programs, which affects utilization patterns across ambulatory clinics, hospitals, and homecare settings. Additionally, the proliferation of injectable delivery formats has introduced new logistics and patient education imperatives that manufacturers must address to ensure adherence and real-world effectiveness.

Together, these shifts require companies to pivot from product-centric launches toward integrated ecosystem plays that align clinical evidence generation, patient support services, and dynamic pricing approaches. Strategic differentiation will be achieved by those who can demonstrate durable outcomes, operationalize scalable distribution models, and collaborate effectively with payers and providers to lower barriers to long-term access.

An analysis of how the 2025 U.S. tariff adjustments reverberated through procurement, manufacturing realignment, payer coverage, and access strategies across the obesity drug ecosystem

U.S. tariff adjustments in 2025 created a ripple effect across the anti-obesity therapeutic value chain, amplifying vulnerabilities in import-dependent components and altering cost calculus for finished products. Raw material sourcing for biologics and complex small molecules often crosses multiple borders; tariffs on intermediate goods increased landed costs and incentivized firms to reevaluate supplier footprints. In response, procurement teams accelerated supplier diversification and explored forward contracts to hedge input-price volatility.

Manufacturers also reassessed global manufacturing footprints and considered nearshoring options to reduce exposure to tariff-induced price swings. This strategic realignment carries nontrivial implications for capacity planning, technology transfer timelines, and regulatory submissions, since moving production or altering supplier lists requires time-consuming validation and potential inspections by health authorities. Those delays can defer launches and complicate inventory planning for high-demand injectables, which are sensitive to cold-chain integrity and lead times.

Payers and providers reacted to increased product costs by tightening formulary placement and intensifying utilization management. Coverage policies leaned more heavily on prior authorization criteria tied to comorbidity profiles and demonstrated response, while some health systems increased their emphasis on cost-mitigating alternatives such as nonpharmacologic interventions or legacy oral agents. At the same time, manufacturers with vertically integrated supply chains or domestic production capability enjoyed a relative advantage, securing continuity of supply and greater pricing flexibility. In sum, tariff-driven pressures reinforced the strategic value of supply chain resilience, regulatory agility, and proactive stakeholder engagement to preserve patient access and commercial momentum.

Detailed segmentation insights linking product modality, dosage form, administration route, and end-user settings to distinct clinical and commercial opportunities

Segmentation-based analysis reveals differentiated opportunities and constraints across therapeutic, dosage, administration, and end-user vectors that should shape portfolio and commercial strategies. Based on product type, GLP-1 agonists and dual-agonist modalities are driving clinician demand through high-efficacy outcomes, while established agents such as naltrexone-bupropion, orlistat, phentermine-topiramate, and SGLT2 inhibitors retain relevance for specific patient cohorts and comorbidity-driven prescribing. Differing mechanisms of action and safety profiles mean that treatment sequencing, combination strategies, and contraindication management will remain central to clinical messaging.

Dosage form considerations materially influence patient adoption and supply chain design. The market's injectable formats, which include prefilled pens and vials, demand robust cold-chain logistics and comprehensive patient education programs to optimize adherence. Capsules and tablets retain advantages in convenience and prescribing simplicity, which can be critical where cost or patient preference limits injectable uptake. Consequently, lifecycle management must account for both clinical differentiation and practical delivery constraints to maximize uptake across diverse settings.

Route of administration further stratifies commercial and clinical strategies. Injectable pathways, including autoinjectors, prefilled pens, and vials, require investment in nurse and pharmacist training, remote monitoring support, and device ergonomics to reduce administration barriers. Nasal and oral routes offer differentiated value propositions for rapid onset or convenience, which can expand reach among patients with injection hesitancy. Finally, end-user segmentation into clinics, homecare settings, and hospitals influences distribution choices, channel economics, and the design of patient support services. Clinics and hospital outpatient programs often serve as early adopters for higher-acuity cases, while homecare services are increasingly central to chronic therapy adherence and long-term retention.

Regional variations in clinical adoption, payer requirements, and regulatory complexity driving differentiated access strategies across the Americas, EMEA, and Asia-Pacific

Regional dynamics exhibit distinct clinical, regulatory, and commercial contours that require tailored strategies for market entry and scale-up. In the Americas, strong payer influence, large-scale clinical adoption, and high patient demand for efficacious therapies create a competitive environment where evidence of long-term outcomes and cost-effectiveness is paramount. Manufacturers that can align with value-based contracting and patient-support infrastructure will find traction in both specialty clinics and broader ambulatory networks.

Europe, Middle East & Africa presents a heterogeneous landscape characterized by variable regulatory pathways, divergent reimbursement philosophies, and differing levels of clinical infrastructure. National health systems and regional payers often require more rigorous health technology assessments and comparative-effectiveness data, which increases the importance of region-specific evidence generation and early HTA engagement. In markets where public coverage is constrained, private pay and clinic-based models may drive initial uptake, and partnerships with regional distributors can optimize access.

Asia-Pacific is defined by rapid adoption in urban centers, diverse regulatory timelines, and a mix of public and private payer structures. High population density and increasing prevalence of cardiometabolic comorbidities make the region strategically critical, but manufacturers must navigate price sensitivity, differential prescribing practices, and growing local competition. Across all regions, a coherent approach to regulatory harmonization, local clinical data generation, and tailored patient-support ecosystems will be necessary to translate clinical promise into sustainable access and outcomes.

Competitive dynamics and corporate strategies that determine long-term leadership in anti-obesity therapeutics through evidence generation, supply resilience, and integrated patient solutions

Competitive positioning in the anti-obesity therapeutics arena is being shaped by a mix of established pharmaceutical companies and innovative biotechnology entrants. Market leaders are leveraging deep clinical development capabilities to expand indications and generate head-to-head evidence, while newer entrants are focusing on differentiated mechanisms, device innovation, or integrated patient-support propositions. Strategic partnerships, co-development agreements, and acquisitions are common as firms seek to accelerate pipeline maturation and extend commercial reach.

Companies that integrate robust outcomes data with scalable patient services will gain a competitive edge in payer negotiations and provider adoption. Those with strong manufacturing footprints and supply chain redundancy demonstrate advantage in maintaining continuity of supply during demand fluctuations. In parallel, firms investing in device ergonomics, digital adherence tools, and multidisciplinary care models are better positioned to address real-world effectiveness and retention challenges.

Intellectual property strategies and lifecycle management plans will also determine long-term positioning, particularly as biosimilar and small-molecule competitors enter the mix. Proactive management of regulatory exclusivities, device patents, and formulation improvements can extend commercial viability. Ultimately, companies that align clinical differentiation with operational excellence and payer-centric evidence will lead in converting scientific promise into sustained patient access.

High-impact, implementable recommendations for manufacturers and stakeholders to secure access, strengthen supply chains, and maximize real-world therapeutic value

Industry leaders should prioritize a set of actionable interventions that connect clinical promise to durable commercial outcomes. First, invest in a phased evidence generation plan that pairs pivotal trial data with pragmatic real-world studies designed to demonstrate sustained metabolic and quality-of-life benefits. Early engagement with payers and HTA bodies to align endpoints and evidence packages can reduce downstream access friction.

Second, strengthen supply chain resilience by diversifying suppliers, accelerating qualification of alternate sites, and exploring nearshoring where appropriate to mitigate tariff and logistical risk. Parallel investments in cold-chain capacity and inventory management systems will be crucial for high-demand injectables. Third, design patient support models that address initiation and long-term adherence: build multichannel education for injection technique, leverage digital adherence tools, and coordinate with clinics and homecare providers to create continuity of care.

Fourth, adopt flexible commercial models that include outcomes-based contracting, tiered pricing, and indication-specific formulary strategies. Tailor messaging and patient journeys to administration route and dosage form preferences, and optimize device design to reduce friction. Finally, pursue strategic collaborations for distribution, telehealth integration, and local evidence generation to accelerate access across heterogeneous regional markets. Executing these actions in parallel will materially enhance the probability of sustained uptake and payer alignment.

A rigorous multi-method research framework combining stakeholder interviews, regulatory review, clinical evidence synthesis, and scenario analysis to drive strategic conclusions

The research underpinning this executive summary combined a multi-method approach to ensure balanced, actionable insights. Primary qualitative interviews were conducted with clinicians across endocrinology and bariatric medicine, hospital pharmacy directors, payer policy leads, and supply chain executives to surface near-term operational risks and adoption drivers. Regulatory and clinical guidance documents were systematically reviewed alongside public trial registries to validate therapeutic positioning, safety signals, and endpoints shaping coverage discussions.

Quantitative synthesis drew on prescription trends from public health data, clinical trial outcome reporting, and product approvals to map adoption trajectories and identify channel-centric demand signals. Scenario planning techniques were applied to evaluate tariff impacts, manufacturing reallocation timelines, and potential payer responses under varying cost and supply conditions. Finally, cross-functional workshops with commercial, medical affairs, and regulatory experts informed the development of pragmatic recommendations that balance clinical rigor with commercial reality.

Quality assurance measures included triangulation across multiple data sources, validation of key findings with subject-matter experts, and sensitivity analysis around supply chain assumptions. The resulting methodology prioritizes transparency, replicability, and strategic relevance to support executive decision-making.

Concluding synthesis underscoring the necessity of coordinated evidence, supply resilience, and localized access strategies to convert clinical innovation into sustained patient outcomes

The contemporary anti-obesity drug environment is defined by unprecedented therapeutic potential and complex access dynamics. Scientific innovation has raised the bar for efficacy and shifted expectations around chronic disease management, yet access and affordability considerations, coupled with supply chain and regulatory complexity, temper the pace at which those therapies translate to population-level impact. Decision-makers must therefore integrate clinical, operational, and commercial planning to realize long-term value.

Sustainable success will favor organizations that proactively align evidence generation with payer expectations, build resilient and flexible supply chains, and design patient-centric delivery models that reduce adherence barriers. Regional heterogeneity demands localized strategies that respect regulatory norms and payer decision-making frameworks while leveraging global evidence. Taken together, the path forward requires coordinated action across functions and stakeholders to convert clinical advances into meaningful, equitable patient outcomes.

This conclusion underscores the imperative for timely, evidence-informed strategy execution: firms that move decisively to reconcile clinical innovation with pragmatic access solutions will capture the first-mover advantages in a rapidly evolving therapeutic category.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-Obesity Drugs Market, by Product Type

  • 8.1. Glp-1 Agonists
  • 8.2. Naltrexone Bupropion
  • 8.3. Orlistat
  • 8.4. Phentermine Topiramate
  • 8.5. Sglt2 Inhibitors

9. Anti-Obesity Drugs Market, by Dosage Form

  • 9.1. Capsules
  • 9.2. Injectables
    • 9.2.1. Prefilled Pens
    • 9.2.2. Vials
  • 9.3. Tablets

10. Anti-Obesity Drugs Market, by Route Of Administration

  • 10.1. Injectable
    • 10.1.1. Autoinjector
    • 10.1.2. Prefilled Pen
    • 10.1.3. Vial
  • 10.2. Nasal
  • 10.3. Oral

11. Anti-Obesity Drugs Market, by End User

  • 11.1. Clinics
  • 11.2. Homecare Settings
  • 11.3. Hospitals

12. Anti-Obesity Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Anti-Obesity Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Anti-Obesity Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Anti-Obesity Drugs Market

16. China Anti-Obesity Drugs Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Alvogen Iceland EHF
  • 17.6. Amgen Inc
  • 17.7. Arena Pharmaceuticals Inc
  • 17.8. AstraZeneca plc
  • 17.9. Bayer AG
  • 17.10. Boehringer Ingelheim International GmbH
  • 17.11. Currax Pharmaceuticals LLC
  • 17.12. Eli Lilly and Company
  • 17.13. F Hoffmann La Roche Ltd
  • 17.14. GlaxoSmithKline plc
  • 17.15. Innovent Biologics Inc
  • 17.16. LG Chem Ltd
  • 17.17. Merck and Co Inc
  • 17.18. Novo Nordisk A S
  • 17.19. Pfizer Inc
  • 17.20. Rhythm Pharmaceuticals Inc
  • 17.21. Takeda Pharmaceutical Company Limited
  • 17.22. Teva Pharmaceutical Industries Ltd
  • 17.23. VIVUS LLC
  • 17.24. Zydus Lifesciences Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-OBESITY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTI-OBESITY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NALTREXONE BUPROPION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NALTREXONE BUPROPION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NALTREXONE BUPROPION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORLISTAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORLISTAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORLISTAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PHENTERMINE TOPIRAMATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PHENTERMINE TOPIRAMATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PHENTERMINE TOPIRAMATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY AUTOINJECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY AUTOINJECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY AUTOINJECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 133. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 134. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 136. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 154. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 155. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 157. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 161. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 162. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 164. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)